Dexamethasone-Eluting Cochlear Implant Electrode

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2020

Primary Completion Date

May 5, 2022

Study Completion Date

May 5, 2022

Conditions
Hearing Loss, SensorineuralSensorineural Hearing Loss
Interventions
DEVICE

CIDEXEL implant

The newly developed MED-EL Cochlear Implant incorporates the anti-inflammatory agent dexamethasone (DEX) into the electrode array. The passive elution of DEX during the post-implantation period has the purpose of counteracting the increase of the post-operative impedance induced by the insertion trauma.

Trial Locations (1)

30625

MHH - Medizinische Hochschule Hannover, Hanover

All Listed Sponsors
lead

MED-EL Elektromedizinische Geräte GesmbH

INDUSTRY

NCT04450290 - Dexamethasone-Eluting Cochlear Implant Electrode | Biotech Hunter | Biotech Hunter